在高性心肌病中发展心房的当代治疗方法
Ethan J Rowin1, Mark S Link2, Martin S Maron1
1Lahey Hospital and Medical Center, Burlington, MA (E.J.R., M.S.M., B.J.M.).
Circulation
|November 27, 2023
概括
在心肌缩症 (HCM) 中,心房动会增加中风风险. 包括抗凝血和节律控制在内的当代疗法显著改善了HCM患者的生命质量,并减少了AF患者的死亡率.
科学领域:
- 心脏病学
- 电生理学
- 遗传学
背景情况:
- 前庭动 (AF) 是高性心肌病 (HCM) 的常见并发症,显著增加中风风险,发病率和死亡率.
- 传统的中风风险评分在HCM中不可靠,需要专门的风险评估.
研究的目的:
- 审查目前对HCM患者的AF治疗策略.
- 突出抗凝血,节律控制,节律控制和消融疗法的进步.
主要方法:
- 在HCM中对AF管理的当代文献的审查.
- 对抗凝血,抗心律药物,导管切除和手术切除的治疗结果的分析.
主要成果:
- 系统性口服抗凝药有效降低中风风险,首选直接口服抗凝药.
- 一个新的HCM特异性风险评分 (HCM-AF评分) 有助于识别患有AF风险的患者.
- 对于无症状的AF患者,节律控制是有效的,而对于有症状的患者,节律控制至关重要.
- 导管和手术切除为节律控制提供了可行的选择,当与抗节律药物结合或在肌肉切除过程中进行辅助时,结果会得到改善.
结论:
- 现代疗法显著改善了HCM患者的生命质量,并降低了他们的死亡率.
- 个性化风险评估和量身定制的治疗策略对于最佳管理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
21
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
21
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
845
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
845
Disturbances in Heart Rhythm
972
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
972
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
747
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
747


